Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

Genentech, a member of the Roche Group, has won FDA approval for the first treatment indicated for both relapsing and primary progressive forms of multiple sclerosis (MS). Ocrevus™ (ocrelizumab) is a ...

Newly approved medications for secondary progressive MS can help slow disease progression or treat specific symptoms. Most people who are diagnosed with multiple sclerosis (MS) initially have ...

The vendor onboarding workflow begins with a Microsoft Form, where users submit their requests. These submissions are then routed through a structured approval process involving key stakeholders, such ...